clinical trial · NCT07122986
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
Pfizer·phase1·recruiting·n = 310
Healthy ParticipantsE coli vaccine 1 Dose AE coli vaccine 1 Dose BE coli vaccine 2E coli vaccine 3E coli Vaccine 4 Dose AE coli Vaccine 4 Dose BE coli Vaccine 4 Dose CE coli Vaccine 5 Dose A
brief summary
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
started
Aug 11, 2025
primary completion
May 26, 2028
completion
May 26, 2028
last updated
Jan 21, 2026
official title
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol